Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility of Minimal Residual Disease (MRD) Determination in Pediatric B-Lineage ALL Using Deep Sequencing of the Immunoglobulin Heavy Chain Locus

NCT01629745 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT01629745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01629745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility of Minimal Residual Disease (MRD) Determination in Pediatric B-Lineage ALL Using Deep Sequencing of the Immunoglobulin Heavy Chain Locus
Lead sponsor
Children's Oncology Group
Phase
Observational
Overall status
Completed
Start date
June 30, 2012
Completion date
May 31, 2016
Enrollment
99 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia